Article open access publication

ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies

Cardiovascular Research, Oxford University Press (OUP), ISSN 1755-3245

Volume 104, 3, 2014

DOI:10.1093/cvr/cvu225, Dimensions: pub.1042441847, PMC: PMC4242141, PMID: 25344369,



  1. (1) University of Cape Town, grid.7836.a
  2. (2) Aarhus University Hospital, grid.154185.c, Central Denmark Region
  3. (3) Humanitas Clinical and Research Institute, National Research Council of Italy, Rozzano, Italy
  4. (4) The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews
  5. (5) Hospital Universitari Vall d'Hebron, grid.411083.f
  6. (6) University of Erlangen-Nuremberg, grid.5330.5
  7. (7) Pharmahungary Group, Szeged, Hungary
  8. (8) Semmelweis University, grid.11804.3c
  9. (9) Essen University Hospital, grid.410718.b
  10. (10) Texas Medical Center, grid.416986.4
  11. (11) The University of Texas Health Science Center at Houston, grid.267308.8
  12. (12) University of Chieti-Pescara, grid.412451.7
  13. (13) Hospices Civils de Lyon, grid.413852.9
  14. (14) University of Giessen, grid.8664.c
  15. (15) University Medical Center Utrecht, grid.7692.a


Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.


Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

Aarhus University

Danish Open Access Indicator

2014: Unused

Research area: Medicine

Danish Bibliometrics Indicator

2014: Level 1

Research area: Medicine

Dimensions Citation Indicators

Times Cited: 108

Field Citation Ratio (FCR): 31.4

Relative Citation ratio (RCR): 5.38

Open Access Info